Oncostellae — Other · €500K

Bio & Tech Smart Capital, the Galician life-sciences fund managed by Noso Capital and promoted by Grupo Zendal, invested €500,000 in Oncostellae and joined its board. The investment completes a wider €3.3 million raise (€1.3 million from Inveready, XesGalicia, FiTalent, Unirisco and co-founder Julio Castro, plus ~€2 million via Capital Cell) to fund Phase 2 trials of OST-122 for inflammatory bowel disease.